BIO 2017 International #1: CAR-T Therapies on Solid Tumors

CAR-T Therapies on Solid Tumors Here is an excellent summary by BIOtechNow Editors on the application of CAR-T (Chimeric Antigen Receptor) T-Cell therapies on solid tumors. Up until now CAR-T shows great promise against blood cancers but challenges remain for solid tumors. Here are some of the major companies engaged in CAR-T: Bellicum Pharmaceuticals (BLCM), […]

Continue Reading 0

BIOtech Breakout: Healthcare Stocks Lead the Way

Biotech Breakout Continues with Larger Caps Jumping In Biotechs Soar And Healthcare Sector Leads Despite Health Policy Uncertainty 2017 Biotech Run Has Been Impressive but What Can we Buy Now? The BIO 2017 International Convention in San Diego got a big boost with investors piling into biotechnology and healthcare stocks. Of course many of the […]

Continue Reading 0

Good Day Today: XBI Breaks Through to YTD Highs…Update

Market Update 12n 6/20: Biotechs Continue to Rally IBB up 1.87% to $305.50; XBI up 1.93% to $75.60 As we have covered biotech ETFs in the past the XBI is one of our core positions for aggressive investors. It outperforms because of equally weighted positions where a big move in several mid or small caps […]

Continue Reading 0

Rayno Life Science Portfolio 2017

Rayno Life Science Portfolio 2017 YTD 6/15 Top winners YTD: BLUE up 78.9%,FMI up 121.5%,RHHBY up 13%, ABBV up 12.7%. Top Losers YTD: GILD down 9.5%, BMY down 7%. XBI up 20.9%, our top pick for aggressive portfolios. More volatile than the IBB. Portfolio mix of large cap dividend with smaller cap growth and niche […]

Continue Reading 0

Biotech Avoids Tech Wreck of June 9…Update-2 June 15

June 15-Update 2 after close…Biotechs Down with Techs-Red Screen Day Very few winners today: IBB down 0.77%, XBI down 1.36% to $71.55 near 52 week high of $73. ABBV near new highs at $70.60, BLUE up 24.7% for past month. EPZM soars 17% on EZH2 inhibitor, RXDX up 5.8% continues run on NTRK inhibitor. Trump Executive […]

Continue Reading 0

ASCO Update #2: Stock Performance Data as of 6/8/17

ASCO Update: Many Stocks Rallied on the News Over the Past Month ASCO Rally is Holding but Fails to Break Through to New 2017 Highs The stock performance of most companies with ASCO news is summarized below.Biotechnology stocks are driven by clinical and deal news so here are some trends to consider: Anticipation of positive […]

Continue Reading 0

ASCO Update: Movers on the News-INCY PBYI RHHBY

June 5…ASCO Update: Incyte Puma and Roche A lot of the product news is already “baked into” stock prices but here is a brief summary of big movers today on clinical news updates. The bellwether XBI peaked at $71.72 today and is down 0.62% to $70.66. bluebird bio (BLUE) up 8.5% to $91.30 BLUE soared […]

Continue Reading 0

Biotechs Sink Again in Sector Shift to Technology Stocks: Update-1

6/1/17 Update at close…Biotechs Bounce off Bottom of 3 Month Trading Range IBB up 1.8% back above $290 after hitting 200 SMA bottom. XBI up 2.7% to $69.54 at SMA 50. XBI 2017 top is $72. XLV a safer play up over 1% to $76.91; above March highs and near 12 mo. highs up 11.58% […]

Continue Reading 0

Biotech Fades After ASCO Abstract Rally

Biotech Fades with Profit Taking: Is the pre-ASCO Momentum Gone?  Technicals Matter  Drug Pricing Scrutiny Continues Biotechs faded today now that the rush of oncology drug news slowed down. NASDAQ retained momentum with the ETF leader QQQ up 19% YTD pulling ahead of the biotech ETFs. Large cap tech stocks rule. The large cap centric […]

Continue Reading 0

ASCO Abstracts Week: Biotech Trends and Hot Stocks

Biotech Trends: Immuno-Oncology Stocks Trending Strong Await ASCO Meeting on June 2 Prices as of Monday 11:45A with NASDAQ up 0.73% FBT $106.75 up 0.2%, IBB flat at $290.64, XBI at $69.33 up 0.3% Here is a selection of  biotech trending stocks that have had significant moves or released ASCO Abstract news last week. The […]

Continue Reading 0